Novel Intermittent Dosing Burst Paradigm in Spinal Cord Stimulation

Timothy R Deer, Denis G Patterson, Javid Baksh, Jason E Pope, Pankaj Mehta, Adil Raza, Filippo Agnesi, Krishnan V Chakravarthy, Timothy R Deer, Denis G Patterson, Javid Baksh, Jason E Pope, Pankaj Mehta, Adil Raza, Filippo Agnesi, Krishnan V Chakravarthy

Abstract

Introduction: Intermittent dosing (ID), in which periods of stimulation-on are alternated with periods of stimulation-off, is generally employed using 30 sec ON and 90 sec OFF intervals with burst spinal cord stimulation (SCS). The goal of this study was to evaluate the feasibility of using extended stimulation-off periods in patients with chronic intractable pain.

Materials and methods: This prospective, multicenter, feasibility trial evaluated the clinical efficacy of the following ID stimulation-off times: 90, 120, 150, and 360 sec with burst waveform parameters. After a successful trial (≥50% pain relief) using ID stimulation, subjects were titrated with OFF times beginning with 360 sec. Pain, quality of life, disability, and pain catastrophizing were evaluated at one, three, and six months after permanent implant.

Results: Fifty subjects completed an SCS trial using ID stimulation settings of 30 sec ON and 90 sec OFF, with 38 (76%) receiving ≥50% pain relief. Pain scores were significantly reduced from baseline at all time points (p < 0.001). Improvements in quality of life, disability, and pain catastrophizing were aligned with pain relief outcomes; 45.8% of the subjects that completed the six-month follow-up visit used an OFF period of 360 seconds.

Conclusions: ID burst SCS effectively relieved pain for six months. The largest group of subjects used IDB settings of 30 sec ON and 360 sec OFF. These findings present intriguing implications for the optimal "dose" of electricity in SCS and may offer many advantages such as optimizing the therapeutic window, extending battery life, reducing recharge burden and, potentially, mitigating therapy habituation or tolerance.

Keywords: chronic pain; cycling; intermittent dosing burst; spinal cord stimulation.

© 2020 The Authors. Neuromodulation: Technology at the Neural Interface published by Wiley Periodicals LLC on behalf of International Neuromodulation Society.

Figures

Figure 1
Figure 1
Schematic representation of post‐trial IDB titration process. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
(a): IDB program usage at the six‐month follow‐up visit. (b) Average ODI scores at the six‐month follow‐up of subjects who used the three shorter OFF periods and subjects who used the longer OFF periods (150, 120, and 90 sec OFF). Error bars represents 95% confidence intervals. Statistical differences were observed between the two OFF groups using a Mann–Whitney test. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 3
Figure 3
Effect of titrated IDB SCS on pain. Overall (a), back (b), and leg (c) average pain at baseline and at follow‐up visits (p < 0.001). Error bars represents 95% confidence intervals. Statistical differences were observed between baseline and all other follow‐up visits using Friedman's test. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 4
Figure 4
Effect of titrated IDB SCS on subjects' functionality. (a) Average EQ‐5D scores at baseline, trial and at follow‐up visits (p < 0.001); dashed line represents U.S. population norm for age group 55–64 years (0.776 (22)), error bars represents 95% confidence intervals. Statistical differences were observed between baseline and all other follow‐up visits using Friedman's test. (b) Percentage of subjects in each of the Oswestry Disability Index categories at baseline, trial, and at follow‐up visits. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 5
Figure 5
Effect of titrated IDB SCS on subjects' perception of pain and impression of change. (a) Average Pain Catastrophizing Scale scores (p < 0.001); dashed line represents nonpain population norm (13.9 (20)), error bars represents 95% confidence intervals. Statistical differences were observed between baseline and all other follow‐up visits using Friedman's test. (b) Average Pain Catastrophizing Scale subcomponents, error bars represent 95% confidence intervals. (c) Patient General Impression of Change at the six‐month follow‐up visit; blue box contains the categories that reported “somewhat better” or more marked impression of change. [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Borsook D. A future without chronic pain: neuroscience and clinical research. Cerebrum 2012;2012:7–23.
    1. Prager J. Estimates of annual spinal cord stimulator implant rises in the United States. Neuromodulation. 2010;13:68–69.
    1. Taylor RS. Spinal cord stimulation in complex regional pain syndrome and refractory neuropathic back and leg pain/failed fack surgery syndrome: results of a systematic review and meta‐analysis. J Pain Sympt Manage 2006;31:S13–S19.
    1. Nissen M, Ikaheimo TM, Huttunen J, Leinonen V, von und zu Fraunberg M. Long‐term outcome of spinal cord stimulation in failed back surgery syndrome: 20 years of experience with 224 consecutive patients. Neurosurgery 2019;84:1011–1018.
    1. Maher DP, Martins YC, Doshi T et al. Neuropathic pain medication use does not alter outcomes of spinal cord stimulation for lower extremity pain. Neuromodulation 2018;21:106–113.
    1. Kumar K, Taylor RS, Jacques L et al. The effects of spinal cord stimulation in chronic pain are sustained: a 24‐month follow‐up of the prospective randomized controlled multicenter trial of the effectivness of spinal cord stimulation. Neurosurgery 2008;63:762–770.
    1. Taylor RS, Desai MJ, Rigoard P, Taylor RJ. Predictors of pain relief following spinal cord stimulation in chronic back and leg pain and failed back surgery syndrome: a systematic review and meta‐regression analysis. Pain Pract 2014;14:489–505.
    1. De Ridder D, Vancamp T, Vanneste S. Fundamentals of burst stimulation of the spinal cord and brain. In: Krames ES, Peckham PH, Rezai AR, editors. Neuromodulation: comprehensive textbook of principles, technologies, and therapies. 2nd ed. London, UK: Academic Press; 2018.
    1. De Ridder D, Vanneste S, Plazier M, Van Der Loo E, Menovsky T. Burst spinal cord stimulation: toward paresthesia‐free pain suppression. Neurosurgery 2010;66:986–990.
    1. Deer T, Slavin KV, Amirdelfan K et al. Success using neuromodulation with BURST (SUNBURST) study: results from a prospective, randomized controlled trial using a novel burst waveform. Neuromodulation 2018;21:56–66.
    1. Chakravarthy K, Malayil R, Kirketeig T, Deer T. Burst spinal cord stimulation: a systematic review and pooled analysis of real‐world evidence and outcomes data. Pain Med 2019;20:S23–S30.
    1. Falowski SM. An observational case series of spinal cord stimulation waveforms visualized on intraoperative neuromonitoring. Neuromodulation 2019;22:219–228.
    1. De Ridder D, Plazier M, Kamerling N, Menovsky T, Vanneste S. Burst spinal cord stimulation for limb and back pain. World Neurosurg 2013;5:642–649.
    1. Yearwood T, De Ridder D, Yoo HB et al. Comparison of neural activity in chronic pain patients during tonic and burst spinal cord stimulation using fluorodeoxyglucose positron emission tomography. Neuromodulation 2020;23:56–63.
    1. Wolter T, Winkelmuller M. Continuous versus intermittent spinal cord stimulation: an analysis of factors influencing clinical efficacy. Neuromodulation 2012;15:13–19.
    1. Weisshaar CL, Kent AR, Venkatesan L, Winkelstein BA. Comparison of burst SCS paradigms on acute spinal neuronal activity in a rat model of painful radiculopathy. San Diego, CA: Paper presented at American Society of Regional Anesthesia and Pain Medicine, 2016.
    1. Vesper J, Slotty P, Schu S et al. Burst SCS microdosing is as efficacious as standard burst SCS in treating chronic back and leg pain: results from a randomized controlled trial. Neuromodulation. 2019;22:190–193.
    1. Szende A, Oppe M, Devlin N. EQ‐5D value sets: inventory, comparative review and user guide (EuroQol group monographs). Dordrecht, The Netherlands: Springer, 2010.
    1. Fairbank JC, Couper J, Davies JB. The Oswestry low back pain disability questionnaire. Physiotherapy 1980;66:271–273.
    1. Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain Catastrophizing Scale: further psychometric evaluation with adult samples. J Behav Med 2000;23:351–365.
    1. Aiudi CM, Dunn RY, Burns SM et al. Loss of efficacy to spinal cord stimulator therapy: clinical evidence and possible causes. Pain Physician 2017;20:E1073–E1080.
    1. Szende A, Janssen B, Cabases J, editors. Self‐reported population health: an international perspective based on EQ‐5D. Dordrecht/Heidelberg/New York/London: Springer; 2014.
    1. Miller JP, Eldabe S, Buchser E, Johanek LM, Guan Y, Linderoth B. Parameters of spinal cord stimulation and their role in electrical charge delivery: a review. Neuromodulation 2016;19:373–384.
    1. Shealy CN, Mortimer JT, Hagfors NR. Dorsal column electroanalgesia. J Neurosurg 1970;32:560–564.
    1. North RB, Fischell TA, Long DM. Chronic stimulation via percutaneously inserted epidural electrodes. Neurosurgery 1977;1:215–218.
    1. Agnesi F, Johnson MD, Vitek JL. Deep brain stimulation: how does it work? Handb Clin Neurol 2013;116:39–54.
    1. Kumar K, Malik S, Demeria D. Treatment of chronic pain with spinal cord stimulation versus alternative therapies: cost‐effectiveness analysis. Neurosurgery 2002;51:106–116.
    1. Hornberger J, Kumar K, Verhulst E, Clark MA, Hernandez J. Rechargeable spinal cord stimulation versus nonrechargeable system for patients with failed back surgery syndrome: a cost‐consequences analysis. Clin J Pain 2008;24:244–252.
    1. Taylor RS, Ryan J, O'Donnell R, Eldabe S, Kumar K, North RB. The cost‐effectiveness of spinal cord stimulation in the treatment of failed back surgery syndrome. Clin J Pain 2010;26:463–469.
    1. Van Buyten JP, Wille F, Smet I et al. Therapy‐related explants after spinal cord stimulation: results of an international retrospective chart review study. Neuromodulation. 2017;20:642–649.
    1. Lam CK, Rosenow JM. Patient perspectives on the efficacy and ergonomics of rechargeable spinal cord stimulators. Neuromodulation. 2010;13:218–223.
    1. De Ridder D, Vanneste S, Plazier M, Vancamp T. Mimicking the brain: evaluation of St. Jude Medical's prodigy chronic pain system with burst technology. Exp Rev Med Dev 2015;12:143–150.
    1. de Vos CC, Bom MJ, Vanneste S, Lenders MWPM, de Ridder D. Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy. Neuromodulation. 2013;17:152–159.

Source: PubMed

3
Sottoscrivi